WO2020084104A1 - Engineered fc - Google Patents

Engineered fc Download PDF

Info

Publication number
WO2020084104A1
WO2020084104A1 PCT/EP2019/079131 EP2019079131W WO2020084104A1 WO 2020084104 A1 WO2020084104 A1 WO 2020084104A1 EP 2019079131 W EP2019079131 W EP 2019079131W WO 2020084104 A1 WO2020084104 A1 WO 2020084104A1
Authority
WO
WIPO (PCT)
Prior art keywords
region
antigen
polypeptide
position corresponding
binding
Prior art date
Application number
PCT/EP2019/079131
Other languages
English (en)
French (fr)
Inventor
Jerome Douglas BOYD-KIRKUP
Piers INGRAM
Vicente SANCENON
Original Assignee
Hummingbird Bioscience Holdings Pte. Ltd.
CLEGG, Richard Ian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Pte. Ltd., CLEGG, Richard Ian filed Critical Hummingbird Bioscience Holdings Pte. Ltd.
Priority to CN201980070848.2A priority Critical patent/CN112912393A/zh
Priority to EP19801222.1A priority patent/EP3870605A1/en
Priority to US17/288,245 priority patent/US20210388083A1/en
Publication of WO2020084104A1 publication Critical patent/WO2020084104A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PCT/EP2019/079131 2018-10-25 2019-10-25 Engineered fc WO2020084104A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980070848.2A CN112912393A (zh) 2018-10-25 2019-10-25 工程化的fc
EP19801222.1A EP3870605A1 (en) 2018-10-25 2019-10-25 Engineered fc
US17/288,245 US20210388083A1 (en) 2018-10-25 2019-10-25 Engineered fc

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1817354.2 2018-10-25
GBGB1817354.2A GB201817354D0 (en) 2018-10-25 2018-10-25 Engineered FC

Publications (1)

Publication Number Publication Date
WO2020084104A1 true WO2020084104A1 (en) 2020-04-30

Family

ID=64560497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/079131 WO2020084104A1 (en) 2018-10-25 2019-10-25 Engineered fc

Country Status (6)

Country Link
US (1) US20210388083A1 (zh)
EP (1) EP3870605A1 (zh)
CN (1) CN112912393A (zh)
GB (1) GB201817354D0 (zh)
TW (1) TW202031681A (zh)
WO (1) WO2020084104A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
US7695936B2 (en) 1995-03-01 2010-04-13 Genentech, Inc. Knobs and holes heteromeric polypeptides
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2813568A1 (en) * 2012-02-09 2014-12-17 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2019185878A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3617317A4 (en) * 2017-02-17 2021-01-13 Xiamen University PEPTIDIC SUPPORT FOR THE DISPLAY OF A TARGET POLYPEPTIDE AND ASSOCIATED USE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695936B2 (en) 1995-03-01 2010-04-13 Genentech, Inc. Knobs and holes heteromeric polypeptides
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
EP2813568A1 (en) * 2012-02-09 2014-12-17 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2019185878A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules

Non-Patent Citations (68)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. P01834-1
AHMED ALYSIA A ET AL: "Structural characterization of GASDALIE Fc bound to the activating Fc receptor Fc[gamma]RIIIa", JOURNAL OF STRUCTURAL BIOLOGY, ACADEMIC PRESS, UNITED STATES, vol. 194, no. 1, 2 February 2016 (2016-02-02), pages 78 - 89, XP029422427, ISSN: 1047-8477, DOI: 10.1016/J.JSB.2016.02.001 *
ANNALINA TAMMEN ET AL: "Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells", THE JOURNAL OF IMMUNOLOGY, vol. 198, no. 4, 6 January 2017 (2017-01-06), pages 1585 - 1594, XP055605122, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1601268 *
BOERSMA ET AL., J BIOL CHEM, vol. 286, 2011, pages 41273 - 85
BRINKMANNKONTERMANN, MABS, vol. 9, no. 2, 2017, pages 182 - 212
BRUHNS, BLOOD, vol. 119, 2012, pages 5640 - 5649
CARTER, J IMMUNOL METH, vol. 248, 2001, pages 7 - 15
CARTER, J IMMUNOL METHODS, vol. 248, 2001, pages 7 - 15
CHANDRUDU ET AL., MOLECULES, vol. 18, 2013, pages 4373 - 4388
CHEN ET AL., ADV DRUG DELIV REV, vol. 65, no. 10, 2013, pages 1357 - 1369
CHOI ET AL., MOL CANCER THER, vol. 12, no. 12, 2013, pages 2748 - 59
CHOI ET AL., PLOS ONE, vol. 10, no. 12, 2015, pages e0145349
CHOTHIA ET AL.: "J. Mol. Biol.", vol. 196, 1987, pages: 901 - 917
CHUNG ET AL., MABS, vol. 4, no. 3, 2012, pages 326 - 340
DALL'ACQUA ET AL., J IMMUNOL., vol. 169, 2002, pages 5171 - 5180
DAVIS ET AL., PROTEIN ENG DES SEL, vol. 23, no. 4, 2010, pages 195 - 202
DIEBOLDER ET AL., SCIENCE, vol. 343, no. 6176, 2014, pages 1260 - 3
EMANUEL ET AL., MABS, vol. 3, 2011, pages 38 - 48
FANG ZENG ET AL: "Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 293, no. 49, 16 October 2018 (2018-10-16), US, pages 19127 - 19135, XP055665763, ISSN: 0021-9258, DOI: 10.1074/jbc.RA118.005367 *
FRANKSIPPL, BIOINFORMATICS, vol. 24, 2008, pages 2172 - 2176
FRENZEL ET AL., FRONT IMMUNOL., vol. 4, 2013, pages 217
GONG ET AL., J BIOL CHEM., vol. 284, no. 21, 2009, pages 14203 - 10
GREENSAMBROOK: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR PRESS
HA ET AL., FRONT. IMMNOL, vol. 7, no. 394, 2016, pages 394
HE ET AL., J PHARM SCI., 2010
HEARTY ET AL., METHODS MOL BIOL, vol. 907, 2012, pages 411 - 442
IDUSOGIE ET AL., J IMMUNOL., vol. 166, no. 4, 2001, pages 2571 - 5
INVIVOGEN: "Engineered Fc Regions ENGINEERING FC REGIONS FOR ALTERED PROPERTIES", 1 January 2011 (2011-01-01), XP055552043, Retrieved from the Internet <URL:https://www.invivogen.com/sites/default/files/invivogen/resources/documents/reviews/review-Engineered-Fc-Regions-invivogen.pdf> [retrieved on 20190205] *
JEDEMA ET AL., BLOOD, vol. 103, 2004, pages 2677 - 82
JEFFERIS ET AL., IMMUNOL REV, vol. 163, 1998, pages 59 - 76
JONG ET AL., PLOS BIOL., vol. 14, no. 1, 2016, pages e1002344
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KAMEN ET AL., J IMMUNOL, vol. 157.17, 1981
KATOHSTANDLEY, MOLECULAR BIOLOGY AND EVOLUTION, vol. 30, no. 4, 2013, pages 772 - 780
KELLNER ET AL., TRANSFUS MED HEMOTHER, vol. 44, 2017, pages 327 - 336
KUNERTREINHART, APPL MICROBIOL BIOTECHNOL., vol. 100, 2016, pages 3451 - 3461
LAD ET AL., J BIOMOL SCREEN, vol. 20, no. 4, 2015, pages 498 - 507
LASSMANNSONNHAMMER, BMC BIOINFORMATICS, vol. 6, no. 298, 2005
LAZAR ET AL., PROC NATL ACAD SCI USA., vol. 103, 2006, pages 4005 - 4010
LEAVER-FAY ET AL., STRUCTURE, vol. 24, no. 4, 2016, pages 641 - 51
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
LEFRANC ET AL., NUCLEIC ACIDS RES., vol. 43, 2015, pages D413 - 22
MASUDA ET AL., INFLAMM ALLERGY DRUG TARGETS, vol. 8, no. 1, 2009, pages 80 - 86
MOORE ET AL., MABS, vol. 2, no. 2, 2010, pages 181 - 9
MOORE ET AL., MABS, vol. 3, no. 6, 2011, pages 546 - 57
NAT METHODS., vol. 5, no. 2, 2008, pages 135 - 146
NATSUME ET AL., CANCER RES., vol. 68, no. 10, 2008, pages 3863 - 72
NOTREDAME ET AL., J. MOL. BIOL., vol. 302, 2000, pages 205 - 217
PARSLOW ET AL., BIOMEDICINES, vol. 4, no. 3, September 2016 (2016-09-01), pages 14
PATRICK SMITH ET AL: "Mouse model recapitulating human Fc gamma receptor structural and functional diversity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 109, no. 16, 17 April 2012 (2012-04-17), pages 6181 - 6186, XP002691305, ISSN: 0027-8424, [retrieved on 20120402], DOI: 10.1073/PNAS.1203954109/-/DCSUPPLEMENTAL *
PETERSEN ET AL., NATURE METHODS, vol. 8, 2011, pages 785 - 786
PROC NATL ACAD SCI USA., vol. 110, no. 13, 2013, pages 5145 - 50
PROTEIN ENG DES SEL., vol. 26, no. 2, 2013, pages 151 - 64
RETTER ET AL., NUCL. ACIDS RES., vol. 33, no. 1, 2005, pages D671 - D674
REVERDATTO ET AL., CURRTOP MED CHEM., vol. 15, no. 12, 2015, pages 1082 - 1101
RICHARDS ET AL., MOL CANCER THER., vol. 7, 2008, pages 2517 - 2527
SCHLOTHAUER ET AL., PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 29, no. 10, 2016, pages 457 - 466
SCHROEDERCAVACINI J, ALLERGY CLIN IMMUNOL., vol. 125, no. 202, 2010, pages S41 - S52
SHIELDS ET AL., J BIOL CHEM., vol. 276, 2001, pages 6591 - 6604
SODING, J., BIOINFORMATICS, vol. 21, 2005, pages 951 - 960
STAVENHAGEN ET AL., CANCER RES., 2007
STROP ET AL., J MOL BIOL., vol. 420, no. 3, 2012, pages 204 - 19
VON KREUDENSTEIN ET AL., MABS, vol. 5, no. 5, 2013, pages 646 - 236
WANG ET AL., PROTEIN CELL, vol. 9, no. 1, 2018, pages 63 - 73
YAMASHITA ET AL., SCIENTIFIC REPORTS, vol. 6, 2016, pages 19772
ZALEVSKY ET AL., NAT BIOTECHNOL., vol. 28, 2010, pages 157 - 159
ZEMELLA ET AL., CHEMBIOCHEM, vol. 16, no. 17, 2015, pages 2420 - 2431
ZHOUROSSI, NAT REV DRUG DISCOV., vol. 16, no. 3, 2017, pages 181 - 202

Also Published As

Publication number Publication date
US20210388083A1 (en) 2021-12-16
EP3870605A1 (en) 2021-09-01
CN112912393A (zh) 2021-06-04
TW202031681A (zh) 2020-09-01
GB201817354D0 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
US11208498B2 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
EP3645570B1 (en) Vista antigen-binding molecules
US10662241B1 (en) HER3 antigen-binding molecules
US11873346B2 (en) VISTA antigen-binding molecules
WO2019086573A1 (en) Cd47 antigen-binding molecules
WO2019086574A1 (en) Cd47 and cd33 antigen-binding molecules
WO2019110209A1 (en) Cd47 and bcma/taci antigen-binding molecules
US20230374147A1 (en) Bcma/taci antigen-binding molecules
US20210388083A1 (en) Engineered fc
US20240158538A1 (en) Vista antigen-binding molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19801222

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019801222

Country of ref document: EP

Effective date: 20210525